Market Spotlight: Obesity
Market Spotlight: Obesity
$1,318.00
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were approximately 681.3 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 762.9 million prevalent cases by 2026.
- In the same year, Datamonitor Healthcare estimates that there were 126.6 million prevalent cases of obesity in children and adolescents (aged 5–19 years) worldwide, and expects that number to increase to 134.0 million prevalent cases by 2026.
- Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with two products being available in a subcutaneous formulation.
- The largest proportion of industry-sponsored drugs in active clinical development for obesity are in Phase I, with only one drug in Phase III.
- Therapies in development for obesity focus on a wide variety of targets, with the subcutaneous route being the most common method of delivery.
- High-impact upcoming events for drugs in the obesity space comprise a decentralized EU approval and an estimated EU patent expiration for Qsymia, an expected supplemental CHMP opinion for Ozempic, and topline Phase III trial results for tirzepatide.
- The overall likelihood of approval of a Phase I obesity asset is 2.5%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 9.6 years in the overall metabolic space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.
- The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the obesity space is dominated by completed trials. Novo Nordisk has the highest number of completed clinical trials for obesity, with 85 trials.
- Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Medications
9 Surgery
11 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 Ozempic for Obesity (February 10, 2021)
27 Tesomet for Obesity (November 23, 2020)
29 AM833 for Obesity (June 18, 2020)
31 Ozempic for Obesity (June 12, 2020)
33 Ozempic for Obesity (June 4, 2020)
35 Ozempic for Obesity (May 13, 2020)
37 Tesomet for Obesity (April 22, 2020)
39 Efpeglenatide for Obesity (December 10, 2019)
41 KEY UPCOMING EVENTS
42 KEY REGULATORY EVENTS
42 Wegovy Is Novo Nordisk’s GLP-1 Agonist In A New Guise For Obesity
42 Obesity Drug Imcivree Among Eight New Products To Win EMA Nod
42 EMA Recommends Label Extension Of Saxenda For Obesity
42 Five New EU Filings Leave Starting Blocks at EMA
43 EMA Reviews Amfepramone Medicines
43 Review Vouchers: Danyelza, Imcivree Earn; Novo Nordisk Spends
43 Rhythm’s Setmelanotide Loses Fast-Track Status In Europe
44 MAAs Under Review/Rhythm Files Setmelanotide
45 PROBABILITY OF SUCCESS
46 LICENSING AND ASSET ACQUISITION DEALS
46 Piramal Snaps Up Peptide API Specialist Hemmo
46 Boehringer Ingelheim, Gubra Enter Third Obesity Deal
46 Tonix Obtains U. Of Geneva Oxytocin Technology
47 Senda Teams With Nestle Nutritional Health For Metabolic Conditions
47 CMS Pays $35m For China Rights To Gelesis Obesity Therapy
48 CLINICAL TRIAL LANDSCAPE
49 Sponsors by status
50 Sponsors by phase
51 Recent events
53 BIBLIOGRAPHY
54 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of obesity in adults, 2017–26
20 Figure 2: Overview of pipeline drugs for obesity in the US
20 Figure 3: Pipeline drugs for obesity, by company
21 Figure 4: Pipeline drugs for obesity, by drug type
21 Figure 5: Pipeline drugs for obesity, by classification
27 Figure 6: Ozempic for Obesity (February 10, 2021): Phase IIIa – STEP 1 (Weight Loss)
29 Figure 7: Tesomet for Obesity (November 23, 2020): Phase IIa – Hypothalamic Obesity (Denmark)
31 Figure 8: AM833 for Obesity (June 18, 2020): Phase I – w/Semaglutide
31 Figure 9: AM833 for Obesity (June 18, 2020): Phase II – 4433
33 Figure 10: Ozempic for Obesity (June 12, 2020): Phase IIIa – STEP 2 (Overweight/obese diabetics), Phase IIIa – STEP 3 (Maximizing Weight Loss)
35 Figure 11: Ozempic for Obesity (June 4, 2020): Phase IIIa – STEP 1 (Weight Loss)
37 Figure 12: Ozempic for Obesity (May 13, 2020): Phase IIIa – STEP 4 (Maintained Weight Loss)
39 Figure 13: Tesomet for Obesity (April 22, 2020): Phase IIa – Hypothalamic Obesity (Denmark)
41 Figure 14: Key upcoming events in obesity
45 Figure 15: Probability of success in the obesity pipeline
48 Figure 16: Clinical trials in obesity
48 Figure 17: Top 10 drugs for clinical trials in obesity
49 Figure 18: Top 10 companies for clinical trials in obesity
49 Figure 19: Trial locations in obesity
50 Figure 20: Obesity trials status
51 Figure 21: Obesity trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of obesity in adults, 2017–26
14 Table 2: Prevalent cases of morbid obesity in adults, 2017–26
15 Table 3: Prevalent cases of obesity in children and adolescents, 2017–26
16 Table 4: Prevalence proportions of obesity and morbid obesity, 2017
18 Table 5: Marketed drugs for obesity
22 Table 6: Pipeline drugs for obesity in the US
26 Table 7: Ozempic for Obesity (February 10, 2021)
28 Table 8: Tesomet for Obesity (November 23, 2020)
30 Table 9: AM833 for Obesity (June 18, 2020)
32 Table 10: Ozempic for Obesity (June 12, 2020)
34 Table 11: Ozempic for Obesity (June 4, 2020)
36 Table 12: Ozempic for Obesity (May 13, 2020)
37 Table 13: Tesomet for Obesity (April 22, 2020)
40 Table 14: Efpeglenatide for Obesity (December 10, 2019)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Osteoporosis 
Sign up to the